| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
QT Imaging Holdings, Inc.$2.77
+0.06 (+2.21%)
Market Cap
83.21 M
EPS
-2.21
P/E Ratio
-3.12 $
Value Trade
432.11 K
SEC Financials
Q4 2025Dilution Risk
40%Revenue
18.93 M
R&D Expenses
3.94 M
Operating CF
-8.96 M
Total Assets
23.02 M
Total Liabilities
16.58 M
Equity
6.45 M
D/E Ratio
12,345
-17.52 %
Week
6.78 %
1 Month
-51.51 %
3 Month
-39.22 %
6 Month
-95.97 %
5 Year
-95.97 %
All Time
Cash Data
Cash Position
10.41 M
Monthly Burn
747.00 K
Runway
9.8 mo
Burn Trend
SEC Filing
Mar 25, 2026
Overview
Volume
7.62 K
52 Week Range
0.60 - 8.50
% held by Insiders
19.52 %
% held by Institutions
17.87 %
Enterprise Value
78.00 M
Total Shares
12.04 M
Short %
2.41 %
Float Shares
8.07 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in QTI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
QTI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
QTI▲ +2.2%today
QT Imaging Receives Israeli Ministry of Health Regulatory Registration
QT Imaging Holdings, Inc. has received regulatory registration from the Israeli Ministry of Health for its innovative, radiation-free breast imaging scanner. This approval authorizes the company to commercialize the system in Israel until February 2, 2028. The registration is supported by the company's existing clearance from the U.S. FDA.
Read more →QTIQT Imaging Announces Successful Completion of First FDA Routine Inspection with Zero Form 483 Observations
QT Imaging has successfully completed its first FDA routine inspection without receiving any Form 483 observations. This achievement highlights the company's commitment to maintaining high operational standards and compliance with regulatory requirements. The positive outcome of the inspection may enhance QT Imaging's credibility in the biopharma industry.
Read more →QTIQT Imaging’s CEO Presents Sports Shiftmaker Award to Tennis Champion and Breast Cancer Survivor Martina Navratilova During Wimbledon Week
QT Imaging's CEO presented the Sports Shiftmaker Award to tennis champion and breast cancer survivor Martina Navratilova during Wimbledon week. This event underscores the intersection of sports and health awareness, celebrating Navratilova's achievements and resilience. The recognition emphasizes QT Imaging's commitment to promoting health initiatives in the sports community.
Read more →QTIA New Standard of Reproducibility for Quantitative Biomarkers in Breast Imaging
The article discusses advancements in the reproducibility of quantitative biomarkers in breast imaging. It highlights the importance of these developments for improving diagnostic accuracy. However, specific details about the methodologies or results are not provided in the text.
Read more →QTI▼ -7.4%on this news
QT Imaging Receives Saudi Arabia FDA Regulatory Clearance
QT Imaging has successfully obtained regulatory clearance from the Saudi Arabia FDA. This milestone is expected to bolster the company's operations and market reach in the region, potentially leading to increased business opportunities. The approval signifies a step forward for QT Imaging in expanding its influence in the Middle Eastern healthcare market.
Read more →QTIQT Imaging Set to Join the Russell Microcap® Index
QT Imaging has announced its inclusion in the Russell Microcap® Index. This index is known for representing small-cap companies in the U.S. equity market. The move is expected to enhance visibility and attract potential investors to the company.
Read more →QTIinvestorpresentati Quantitative Transmission Imaging Breast Acoustic CT Scanner May 2026 NASDAQ:QTI Copyright 2026 QT Imaging, Inc. All Rights Reserved. 2 Disclaimer ABOUT THIS PRESENTATION This investor presentation (th
QT Imaging, Inc. has released an investor presentation outlining their business model, partnerships, and financial trajectory for the Quantitative Transmission Imaging Breast Acoustic CT Scanner. The presentation aims to provide insights into the market and the company's strategy moving forward. Details regarding the current market context and potential growth opportunities were discussed, signaling a proactive approach to engaging with stakeholders.
Read more →QTIQT Imaging Holdings Announces Closing of $10 Million Underwritten Public Offering
QT Imaging Holdings has announced the successful closing of a $10 million underwritten public offering. This financial move is expected to bolster the company's resources for future projects. Details regarding the use of proceeds and investor interest were not disclosed in the announcement.
Read more →QTI▼ -16.7%on this news· ran to -28% by day 3shared move
QT Imaging Reports First Quarter 2026 Revenue of $6.5 Million
QT Imaging has reported its revenue for the first quarter of 2026, totaling $6.5 million. The announcement highlights the company's financial performance during this period. Further details regarding the revenue sources or future projections were not provided in the article.
Read more →QTI▼ -16.7%on this news· ran to -28% by day 3shared move
Document QT Imaging Reports First Quarter 2026 Revenue of $6.5 Million Revenue of $6.5 Million, Up 133% Year-Over-Year with 13 Scanners Shipped Two Year Extension of the Maturity Date of the Senior Secured Term Loan to
QT Imaging Holdings, Inc. reported a first quarter revenue of $6.5 million, a 133% increase compared to the previous year, following the shipment of 13 Breast Acoustic CT systems. The company secured a Category III CPT code that becomes effective in January 2027, enhancing reimbursement prospects. Additionally, QT Imaging extended the maturity date of its senior secured term loan to March 2029, which provides financial flexibility amid ongoing operational growth. Despite these achievements, the company reported a net loss of $3.4 million and a decrease in gross margin.
Read more →QTI▲ +6.2%on this news· ran to -24% by day 3shared move
Leading Breast Surgical Oncologist Dr. Barry Roseman to Serve as Senior Medical Advisor to QT Imaging
QT Imaging has appointed Dr. Barry Roseman, a leading breast surgical oncologist, as its Senior Medical Advisor. This strategic move aims to leverage Dr. Roseman's expertise to enhance the company's initiatives in breast cancer imaging. His extensive experience is expected to provide valuable insights and guidance.
Read more →QTIQT Imaging to Hold First Quarter 2026 Conference Call on May 13, 2026
QT Imaging Holdings, Inc. will report its financial results for Q1 2026 on May 13, 2026, after market close. A conference call for the investment community will take place at 4:30 p.m. ET on the same day. Participants can pre-register for immediate access or dial in directly. The company is dedicated to advancing breast health management through innovative imaging solutions.
Read more →QTI▲ +8.4%on this news
QT Imaging CEO Discusses the Importance of Early Breast Cancer Detection at the Shiftmakers’ Panel and Gala
The article mentions QT Imaging's CEO discussing early breast cancer detection at the Shiftmakers' Panel and Gala. However, specific details about the discussion or the event itself are not provided. The focus appears to be on the importance of early detection in breast cancer, but further insights are lacking.
Read more →QTIQT Imaging Releases Its Next Generation Breast Imaging Reconstruction Software
QT Imaging Holdings, Inc. has released version 4.5.0 of its breast imaging reconstruction software, enhancing spatial resolution and image quality. The update includes improved visualization through the fusion of speed of sound and reflection data, aiding in tissue characterization. This version also addresses specific clinical scenarios, expanding usability for diverse patient anatomies.
Read more →QTI▲ +5%on this news
QT Imaging Reports 2025 Fourth Quarter and Full Year Financial Results
QT Imaging Holdings, Inc. reported strong financial results for Q4 and the full year 2025, exceeding revenue targets and achieving significant milestones in reimbursement and regulatory approvals. The company anticipates substantial growth in 2026, driven by new partnerships and the rollout of its cloud platform. Despite a net loss, the overall outlook remains positive with strategic advancements in technology and market presence.
Read more →QTI▲ +5%on this news
Document QT Imaging Reports 2025 Fourth Quarter and Full Year Financial Results 2025 Revenue of $18.9 Million Exceeded Outlook with a Record 40 Scanners Shipped Affirms 2026 Revenue Guidance of $39 Million from Contracte
QT Imaging Holdings, Inc. reported its financial results for 2025, with a revenue of $18.9 million, surpassing its $18.0 million forecast. The company highlighted the shipment of a record 40 Breast Acoustic CT scanners and secured its first CPT code, facilitating broader adoption of its technology. Looking forward, QT Imaging anticipates revenue of approximately $39 million for 2026 driven by distributor partnerships and its new QTI Cloud Platform. Despite the successes, the company faced challenges with decreased gross margins and a significant annual net loss.
Read more →QTIQT Imaging Receives UAE Regulatory Clearance
QT Imaging has received regulatory clearance in the UAE, marking a significant step for the company. This approval allows them to advance their operations in the region. The news highlights the company's ongoing efforts to expand its market presence.
Read more →QTIQT Imaging Names Renowned Breast Cancer Researcher Dr. Mary Yamashita as Medical Advisor
QT Imaging has appointed Dr. Mary Yamashita as Medical Advisor to enhance its breast imaging technologies. Dr. Yamashita, a leader in breast cancer research, will provide strategic support in clinical standards and user experience. Her extensive background in breast imaging will help QT Imaging advance its radiation-free imaging solutions and improve patient care.
Read more →QTIQT Imaging Achieves Major Reimbursement Milestone with AMA Category III CPT Code for 3D Breast Ultrasound Tomography
QT Imaging has received approval for a new Category III CPT code for its 3D breast ultrasound technology, marking a significant milestone for the company. This code will standardize reporting and support the adoption of its innovative, radiation-free imaging platform. The effective date for the code is set for January 1, 2027, enhancing QT Imaging's commercial strategy and expanding access to safer breast imaging options.
Read more →QTIQT Imaging Reports Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
QT Imaging Holdings, Inc. reported preliminary unaudited financial results for Q4 and the full year 2025, highlighting record revenue and scanner shipments. The company exceeded its 2025 revenue expectations and successfully relisted on Nasdaq. Looking ahead, QT Imaging anticipates approximately $39 million in revenue for 2026, driven by scanner sales and its SaaS Cloud Platform.
Read more →QTIDocument QT Imaging Reports Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results Generated Record Revenue of $8.3 Million in Q4 2025, up 97% versus Q3 2025 Shipped Record 17 Scanners in Q4 2025 and 4
QT Imaging has reported preliminary unaudited financial results for Q4 and full-year 2025, achieving record revenue of $8.3 million, which reflects a significant growth of 97% compared to the previous quarter. The company shipped a record 17 scanners in Q4 2025 and surpassed its revenue outlook with total revenues of $18.9 million for the year. Despite these successes, QT Imaging faced challenges with a declining gross margin and an increased net loss compared to the previous year. The company continues to transition from a traditional scanner provider to a SaaS and biomarker-driven platform, aiming for long-term growth.
Read more →QTIDocument QT Imaging Holdings, Inc. Audited Consolidated Financial Statements As of and for the Years Ended
QT Imaging Holdings, Inc. has released its audited consolidated financial statements for the years ended December 31, 2024, and 2023. The firm reported a substantial increase in revenue, climbing to $4,878,665 in 2024, compared to $40,355 in 2023. However, the company also experienced a significant net loss, with the total loss for common stockholders rising to $14,170,382. Additionally, the accumulated deficit and total liabilities have increased, indicating ongoing financial challenges for the company.
Read more →QTI▼ -5.1%on this newsshared move
QT Imaging Announces Presentation at SPIE Medical Imaging 2026
QT Imaging Holdings, Inc. announced that its Chief Science Officer, Dr. Bilal Malik, will present at the SPIE Medical Imaging 2026 in Vancouver. His presentation will focus on an automated method for breast boundary extraction in Breast Acoustic CT scans. This method aims to enhance imaging accuracy and support future AI/ML initiatives. The presentation reflects QT Imaging's commitment to improving breast health management through innovative technology.
Read more →QTI▲ +1416.1%on this news
QT Imaging Announces Uplisting to Nasdaq Novato, Calif.
QT Imaging Holdings, Inc. has announced its uplisting from the OTCQB Venture Market to the Nasdaq Capital Market, with trading under the ticker symbol 'QTI' set to commence on January 28, 2026. This move reflects the company's efforts to rebuild after a previous delisting, focusing on advanced breast health imaging technology. CEO Dr. Raluca Dinu emphasized the importance of patient-centered imaging solutions and the expected benefits from increased visibility and shareholder base. The uplisting aligns with QT Imaging's long-term strategic goals and commitment to delivering innovative healthcare solutions.
Read more →QTI▲ +1416.1%on this newsshared move
QT IMAGING HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2025 As Filed Pro Forma Adjustment Pro Forma ASSETS Current assets Cash $ 1,715,400 $ 11,542,915 (1)(2)(3) $ 13,258,3
QT Imaging Holdings, Inc. has released its unaudited pro forma condensed consolidated balance sheet for the period ending September 30, 2025. The company reported a significant increase in cash and stockholders' equity, attributed to recent private placements and successful debt repayments. Total assets increased to approximately $23.5 million, while total liabilities were reduced to $16.1 million after debt adjustments. These financial maneuvers aim to enhance the company's liquidity and operational flexibility going forward.
Read more →QTI▲ +1416.1%on this newsshared move
Document QT Imaging Announces Exclusive Distribution Agreement with Al Naghi Medical for the United Arab Emirates Territory Agreement comes on the heels of Company inking an exclusive distribution agreement with Gulf Med
QT Imaging has established an exclusive distribution agreement with Al Naghi Medical for its QTI Breast Acoustic CT scanners in the UAE. This agreement follows a similar deal with Gulf Medical for Saudi Arabia and is expected to generate over $24 million in revenue. Shipments are set to start in Q2 2026, aiming to address the rising prevalence of breast cancer in the region. The technology offers advanced imaging without the risks associated with traditional methods.
Read more →QTI▲ +1416.1%on this newsshared move
QT IMAGING HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE-MONTH PERIOD ENDED SEPTEMBER 30, 2025 Pro Forma As Filed Adjustment Pro Forma Revenue $ 4,
QT Imaging Holdings, Inc. reported an unaudited pro forma condensed consolidated statement for the three-month period ending September 30, 2025. The company experienced a significant net loss of $4,557,406 with total operating expenses at $3,454,752. Pro forma adjustments were made to reflect the effects of a recent securities private placement and changes in fair value related to warrants and earnout liabilities. The financial statement highlights the firm’s reliance on external financing amid ongoing operating losses.
Read more →QTI▲ +1416.1%on this newsshared move
QT IMAGING HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2025 As Filed Pro Forma Adjustment Pro Forma ASSETS Current assets Cash $ 1,715,400 $ 11,387,913 (1)(2) $ 13,103,313
QT Imaging Holdings, Inc. has released its unaudited pro forma condensed consolidated balance sheet and statement of operations for the period ending September 30, 2025. The report highlights a significant increase in total assets to approximately $23.4 million, largely due to a successful private placement that raised about $18.2 million. However, the company also reported a net loss of nearly $20 million, indicating substantial ongoing financial challenges, including a continued accumulated deficit. Adjustments related to long-term debt repayments and equity securities issued during this period reflect the company's efforts to manage its financial landscape.
Read more →QTI▲ +1416.1%on this newsshared move
Document QT Imaging Reports Strong Third Quarter 2025 Financial Results Generated Revenue of $4.2 Million in Q3 Reaffirms Forecast of $18 Million in Revenue and Shipping a Total of 40 Scanners in Full-Year 2025 Applied t
QT Imaging Holdings reported a strong financial performance for Q3 2025, achieving $4.2 million in revenue, which marks a 339% increase year-over-year. The company announced the strengthening of its financial position through an $18.2 million PIPE transaction and the appointment of new executives, enhancing its leadership team. As part of their growth strategy, QT Imaging has entered into a significant distribution partnership in Saudi Arabia, positioning itself for further global expansion. Despite the positive revenue growth, the company experienced a decline in gross margin and reported a net loss, highlighting ongoing challenges.
Read more →QTI▲ +1416.1%on this newsshared move
Document QT Imaging 3 1 Reverse Stock Split Market Effective on
QT Imaging Holdings, Inc. has enacted a 3-for-1 reverse stock split, effective October 24, 2025, enhancing its approach towards structuring its stock offerings. The adjustment to the public warrants will change their exercise price, which reflects a significant restructuring in their financial strategy. Stockholders are being instructed to follow specific processes regarding their shares. This move is part of QT Imaging’s ongoing efforts to improve its body imaging systems, although they face various uncertainties in their future commercialization efforts.
Read more →QTI▲ +1416.1%on this newsshared move
Document QT Imaging Announces Plans to Relist on Nasdaq Company to Effect 3 1 Reverse Stock Split Novato, Calif.
QT Imaging Holdings, Inc. has announced its plans to relist on the Nasdaq Capital Market by implementing a 3-for-1 reverse stock split. This strategy aims to meet the Nasdaq's requirement for a minimum stock price of $4.00. The company received stockholder approval for the reverse split, which will take effect after market close on October 23, 2025. Management expresses optimism about this move, believing it will create long-term stockholder value and broaden the investor base.
Read more →QTI▲ +1416.1%on this newsshared move
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicita
QT Imaging Holdings, Inc. has announced a private placement financing of $18 million aimed at accelerating growth and preparing for a NASDAQ relisting. The financing will allow the company to repay its senior secured term loan and expand its market activities. The investment includes participation from institutional investors and is expected to solidify QT Imaging's position in the medical imaging sector, particularly in enhancing its offerings with precision imaging technologies. The company is also required to file a registration statement with the SEC for these securities, facing inherent risks in the commercialization of its technologies.
Read more →QTI▲ +1416.1%on this newsshared move
QT IMAGING HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET AS OF JUNE 30, 2025 As Filed Pro Forma Adjustment Pro Forma ASSETS Current assets Cash $ 2,022,180 $ 11,754,165 (1)(2) $ 13,776,345 Restr
QT Imaging Holdings, Inc. has released an unaudited pro forma condensed consolidated balance sheet and statement of operations for the six-month period ending June 30, 2025. The company's current assets have increased significantly to approximately $22.27 million due to recent financing, while the total net loss for the period amounts to about $16.55 million. The financial adjustments made reflect the accounting treatment related to a recent private placement and the repurchase of a warrant, which could offer a clearer financial picture going forward.
Read more →QTI▲ +1416.1%on this newsshared move
QT Imaging Receives $5.0 Million in New Funding from Lynrock Lake to Repurchase and Cancel All Yorkville Warrants Novato, Calif.
QT Imaging Holdings has successfully obtained $5.0 million in funding from Lynrock Lake Master Fund through an amended senior secured term loan. This financing has been utilized to fully repurchase 15 million warrants held by Yorkville, reflecting the company's confidence in its future. The CEO, Dr. Raluca Dinu, emphasizes the potential for shareholder value enhancement resulting from this transaction. QT Imaging focuses on developing innovative body imaging systems aimed at improving health outcomes.
Read more →QTI▲ +1416.1%on this newsshared move
QT IMAGING HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET AS OF MARCH 31, 2025 As Filed Pro Forma Adjustment Pro Forma ASSETS Current assets Cash $ 2,987,503 $ - $ 2,987,503 Restricted cash and c
QT Imaging Holdings, Inc. released its unaudited pro forma condensed consolidated balance sheet as of March 31, 2025. The report indicates total assets of approximately $10.86 million, juxtaposed with current liabilities exceeding $5.28 million and total liabilities over $31 million. The company recorded a substantial net loss of $11.14 million for the period, compounding concerns about its financial position. Additionally, adjustments were made regarding warrant liabilities, which could affect future financial reporting.
Read more →QTI▲ +1416.1%on this newsshared move
QT Imaging Holdings Receives $10.1 Million in New Funding to Support Working Capital and Retire Debt Repays all remaining debt used to fund the 2024 deSPAC process and terminates the SEPA line Novato, Calif.
QT Imaging Holdings has announced the successful acquisition of $10.1 million in financing from Lynrock Lake Master Fund LP. This funding is aimed at strengthening the company's financial position and supporting the manufacturing of 100 body imaging scanners over the next two years, expected to generate $45 million in revenue. The company has also completed repayment of previous debts, allowing them to focus on working capital needs for the upcoming years. However, the realization of their financial projections carries inherent risks, including the development and market acceptance of their new imaging technologies.
Read more →QTI▲ +6.6%on this news
Quantitative Transmission Imaging Breast Acoustic CT Scanner INVESTOR PRESENTATION April 2024 Disclaimer ABOUT THIS PRESENTATION This investor presentation (this "Presentation") is provided for informational purposes onl
QT Imaging Holdings (QTI) presented its investor update highlighting the breakthrough capabilities of its FDA-cleared Breast Scanner. This innovative device employs advanced imaging technology to provide 3D imaging for breast assessment, offering a safe, cost-effective alternative to traditional methods like mammograms. The presentation emphasizes the Scanner's potential to enhance medical imaging through superior specificity and comparable diagnostic performance to MRI without the associated discomfort or radiation. The company’s management team is experienced and recognized in the field, lending credibility to QTI's innovative solutions.
Read more →QTIQT Imaging Holdings names Dr. Raluca Dinu as Acting Chief Executive Officer and Anastas Budagov as Chief Financial Officer Novato, Calif.
QT Imaging Holdings has appointed Dr. Raluca Dinu as Acting Chief Executive Officer and Anastas Budagov as Chief Financial Officer. Effective March 12, 2024, Dr. Dinu brings extensive experience from her previous executive roles and is expected to guide the company's growth in advanced body imaging technologies. Meanwhile, Budagov, who has been with the company since December 2023, assumes the CFO role permanently. The strategic leadership transition marks an important step for QT Imaging as it aims to strengthen its market position.
Read more →QTIQT Imaging Holdings Announces New Ticker Symbol for OTC Warrants and Delisting of Units Novato, Calif.
QT Imaging Holdings, Inc. has announced the update of its warrants' ticker symbol to QTIWW, effective from March 11, 2024. This change comes alongside the delisting of its units from the OTC market, following a business combination that occurred on March 4, 2024. The company's focus remains on the research and development of innovative body imaging systems aimed at improving health outcomes.
Read more →QTI▲ +9.4%on this news
QT Imaging Pioneers Patient-Centric Breast Imaging Technology through Strategic Partnership Novato, Calif.
QT Imaging Holdings, Inc. announces the first commercial sale of its QTI Breast Acoustic CTTM System to True Health Center, marking a significant milestone for patient-centric breast imaging. This advanced system eliminates discomfort associated with traditional mammography, avoids radiation exposure, and offers high-resolution 3D images. The QTI Breast Acoustic CTTM System has been validated by the National Institutes of Health, underscoring its potential in enhancing breast imaging standards. The partnership highlights a commitment to improving patient care and safety in medical imaging.
Read more →QTIQT Imaging Holdings Announces Completion of Business Combination with GigCapital5 Combined Company s Innovative Body Imaging Scanning Systems Using Low Frequency Sound Waves Provide Critical Solutions for Detection, Diag
QT Imaging Holdings, Inc. has completed its business combination with GigCapital5, enabling it to operate as a public company under the ticker QTI, starting March 5, 2024. The merger is expected to enhance QT Imaging's presence in the expanding medical imaging market, particularly in cancer detection and diagnosis with its innovative low-frequency sound wave technology. This technology aims to offer more patient-friendly imaging options compared to traditional methods. The business combination positions QT Imaging to capitalize on a growing market estimated to reach approximately $472 billion by 2033.
Read more →QTIUNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION QT Imaging Holdings, Inc. (f/k/a GigCapital5, Inc.) (the Company ) is providing the following unaudited pro forma condensed combined financial information to a
QT Imaging Holdings, Inc. has released its unaudited pro forma condensed combined financial information following the merger with GigCapital5, Inc., which was completed on March 4, 2024. This document details the financial aspects of the merger and adjustments relating to the combined entities. The merger implications include that GigCapital5 will be treated as the acquired company for reporting purposes, reflecting QT Imaging's ongoing operations. Stakeholders should consider that the financial results may not accurately forecast future performance due to the nature of the unaudited data and the existing accumulated deficits.
Read more →QTIGIGCAPITAL5, INC. ANNOUNCES CLOSING DATE FOR BUSINESS COMBINATION WITH QT IMAGING QT Imaging Holdings, Inc. Expected to Begin Trading on Nasdaq Under Ticker Symbols QTI on
GigCapital5, Inc. has announced the completion date of its business combination with QT Imaging Holdings, Inc., set for March 4, 2024. Following this, QT Imaging's shares will commence trading on Nasdaq under the ticker symbol QTI on March 5, 2024. QT Imaging focuses on developing innovative body imaging systems, and this merger is expected to enhance its operational capacity and market presence. The leadership from both organizations expressed confidence in the new venture's potential for growth and impact in the healthcare sector.
Read more →QTIGigCapital5, Inc. Announces Shareholder Approval of Business Combination Palo Alto, CA
GigCapital5, Inc. announced that its shareholders approved the business combination with QT Imaging, Inc. at an annual meeting held on February 20, 2024. This merger will lead to QT Imaging becoming a wholly owned subsidiary of GigCapital5, which will also rebrand it as QT Imaging Holdings, Inc. The transaction, while widely supported, faces potential challenges including regulatory approvals and market conditions that could affect the merger's anticipated benefits. Forward-looking statements in the press release highlight various risks associated with the business combination.
Read more →QTIUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than th
GigCapital5 has announced an extension to the deadline for stockholders to exercise their redemption rights concerning the proposed business combination with QT Imaging. Originally set to expire on February 15, 2024, the new deadline is now February 16, 2024, due to a procedural error at a transfer company. The business combination aims to merge QT Imaging into GigCapital5 and revitalize its operations. GigCapital5 is focused on securing future growth within sectors like healthcare technology, media, and telecommunications.
Read more →QTIUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A/A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than
GigCapital5, Inc. is advancing its merger with QT Imaging by filing a proxy statement that seeks stockholder approval for the business combination. The document includes updates on a letter of intent with Canon Medical Systems regarding the sale and service of QT Imaging products. Additionally, QT Imaging has entered into purchase orders with Canon for QT scanners, with payment structures and feasibility studies outlined. Successful execution of these agreements may lead to further commercialization opportunities for QT Imaging under Canon's global channels.
Read more →QTIGigCapital5, Inc. Announces Stockholder Approval of Extension Amendment to the Amended and Restated Certificate of Incorporation and Investment Management Trust Agreement Palo Alto, CA
GigCapital5, Inc. announced that its stockholders have approved an extension to the business combination deadline from December 28, 2023, to March 31, 2024. This extension is intended to provide more time for GigCapital5 to find viable merger opportunities. The company, a special purpose acquisition company (SPAC), is actively seeking targets in various industries, including technology and healthcare. The extension's approval is seen as a strategic move to enhance the chances of a successful merger with QT Imaging.
Read more →QTIGigCapital5, Inc. Confirms Receipt of Sponsor Funds for Additional Working Capital Palo Alto, CA
GigCapital5, Inc. announced the receipt of $381,360 in additional sponsor funds, increasing their working capital note to $1,446,360. This financial backing comes in advance of their proposed merger with QT Imaging, which aims to further enhance the company's position in the market. The amendment in the promissory note allows for conversion into units at a specified price following the merger. Stakeholders are advised to review the upcoming proxy statement regarding the business combination.
Read more →QTIGigCapital5, Inc. Confirms Consideration for Non-Redemption Agreements Palo Alto, CA
GigCapital5, Inc. has confirmed its consideration for Non-Redemption Agreements ahead of its scheduled special meeting with stockholders set for September 28, 2023. These agreements are part of a settlement with QT Imaging and are aimed at encouraging stockholders to refrain from redeeming their shares, enhancing the likelihood of a successful Business Combination. The merger with QT Imaging is set to create QT Imaging Holdings, Inc., which will serve as a wholly owned subsidiary of GigCapital5. As the completion of this merger is contingent on stockholder approval, investors are being urged to engage with the forthcoming proxy statements for detailed information.
Read more →QTIGigCapital5, Inc. Confirms Receipt of Sponsor Funds to Extend Period of Time to Consummate Business Combination and for Additional Working Capital Palo Alto, CA
GigCapital5, Inc. has confirmed receipt of $100,000 in sponsor funds aimed at extending the deadline for completing its business combination with QT Imaging until August 28, 2023. The company's financial support also includes an amended working capital note totaling $1,065,000. The merger with QT Imaging, a provider of advanced medical imaging solutions, is expected to enhance GigCapital5's market presence once finalized, although there are risks related to regulatory approvals and stockholder votes that could delay the process.
Read more →QTIGigCapital5, Inc. Announces Transfer of Listing To Nasdaq
GigCapital5, Inc. has announced its intention to transfer its stock listing from the NYSE to Nasdaq around April 26, 2023. This move is part of the company’s business combination with QT Imaging, which will lead to GigCapital5 being renamed QT Imaging Holdings, Inc. Following the change, the common stock will be traded under the symbol GIA on Nasdaq, while units and warrants will still trade on the OTC Markets. The company aims to align itself with other innovative technology firms listed on Nasdaq through this transition.
Read more →QTIQT Imaging and GigCapital5 Announce Signing of Business Combination Agreement to Bring Breast and Full Body Imaging Solutions to the Public Markets PALO ALTO, CA. & NOVATO, CA
QT Imaging and GigCapital5 Announce Signing of Business Combination Agreement to Bring Breast and Full Body Imaging Solutions to the Public Markets ALTO, CA. & NOVATO, CA, Dec. 12, 2022 GigCapital5, Inc. (NYSE: GIA), a publicly traded special purpose acquisition company ( GigC
Read more →QTIGigCapital5 and QT Imaging Sign an Exclusive Term Sheet for a Business Combination QT Imaging expected to be public in the first half of 2023 PALO ALTO, CA. & NOVATO, CA
GigCapital5 and QT Imaging Sign an Exclusive Term Sheet for a Business Combination QT Imaging expected to be public in the first half of 2023 PALO ALTO, CA. & NOVATO, CA, Oct. 3, 2022 GigCapital5, Inc. (NYSE: GIA), a publicly traded special purpose acquisition company ( GigCap
Read more →QTIGigCapital5, Inc. Announces a One-Month Extension of the Combination Period Palo Alto, CA
GigCapital5, Inc. Announces a One-Month Extension of the Combination Period Palo Alto, CA September 26, 2022 GigCapital5, Inc. ( GigCapital5 or the Company ) (NYSE: GIA.U; GIA; GIA.WS), a blank check company, also commonly referred to as a special purpose acquisition company, o
Read more →QTIGigCapital5, Inc. Announces Stockholder Approval of Extension Amendments to the Amended and Restated Certificate of Incorporation and Investment Management Trust Agreement Palo Alto, CA
GigCapital5, Inc. Announces Stockholder Approval of Extension Amendments to the Amended and Restated Certificate of Incorporation and Investment Management Trust Agreement Palo Alto, CA September 23, 2022 GigCapital5, Inc. ( GigCapital5 or the Company ) (NYSE: GIA.U; GIA; GIA.
Read more →QTIDr. Sharmila Makhija Joins GigCapital5 Board of Directors
Dr. Sharmila Makhija Joins GigCapital5 Board of Directors PALO ALTO, Calif., January 5, 2022 GigCapital5, Inc. (NYSE: GIA, GIA.U, GIA.WS) (the Company or GigCapital5 ) today announced that Dr. Sharmila Makhija, MD, MBA, an international expert on gynecologic cancer, has joined
Read more →QTIGigCapital5, Inc. Announces the Separate Trading of its Common Stock and Warrants Commencing
GigCapital5, Inc. Announces the Separate Trading of its Common Stock and Warrants Commencing November 4, 2021 ALTO, Calif., November 1, 2021 GigCapital5, Inc. (NYSE: GIA.U) (the Company or GigCapital5 ) today announced that holders of the Company s public units may elect to sep
Read more →QTIGIGCAPITAL5, INC. INDEX TO BALANCE SHEET AND NOTES TO BALANCE SHEET Report of lndependent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNT
TO BALANCE SHEET AND NOTES TO BALANCE SHEET Report of lndependent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of GigCapital5, Inc
Read more →QTIGigCapital5, Inc. Announces Pricing of $200,000,000 Initial Public Offering
GigCapital5, Inc. Announces Pricing of $200,000,000 Initial Public Offering PALO ALTO, Calif. September 23, 2021 GigCapital5, Inc. (NYSE: GIA.U) (the Company or GigCapital5 ) today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per
Read more →Competitive Position
How QTI ranks across every disease it competes inCompetitive Position is a premium feature
See how QTI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial